MLN8237 (Alisertib), a selective Aurora A Kinase (AAK) inhibitor, in patients with relapsed/refractory Small Cell Lung Cancer (SCLC): Phase 2 results - Havel, L; Dees, C; Lockhart, C (J Thoracic Oncol, 2013)
et al.